COMMUNIQUÉS West-GlobeNewswire

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
14/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
Syneos Health Expands Strategic AI Partnerships to Advance Commercial Precision Performance
14/05/2026
MORRISVILLE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Syneos Health ® today announced new and expanded strategic partnerships that strengthen its cutting-edge, AI ecosystem. These innovative solutions represent best-in- [...]
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
14/05/2026
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD- [...]
Sonablate Launches SONA FUSION Global Registry to Advance Precision Sound Medicine and Define Future Standards in Focal Therapy
14/05/2026
First multinational initiative dedicated to long-term HIFU outcomes in prostate cancer and BPH aims to help close the evidence gap in incision-free prostate care CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- [...]
CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale’s Biotech Spinouts
14/05/2026
New Haven-based biotech venture creation platform focused on launching early-stage therapeutics companies from breakthrough Yale University research NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- CapeHaven , LLC, a [...]
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
14/05/2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) ( [...]
Easy Environmental Solutions & Terreplenish® Show Outstanding Yield Increases & Offer Alternative To Petroleum-Based Fertilizers
14/05/2026
Terreplenish® leads the way as company responds to worldwide nitrogen shortage MANKATO, Minn., May 14, 2026 (GLOBE NEWSWIRE) -- Easy Environmental Solutions, Inc. (OTC: EZES) continues to offer a true solution to the [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Administrative Experience Emerges as Key Pressure Point for Self-Funded Plans, Brighton Health Plan Solutions Survey Finds
14/05/2026
New report shows employee satisfaction remains high, but trust can break down when administrative friction gets in the way NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Self-funded health plans are working for many health [...]
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
14/05/2026
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
14/05/2026
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition [...]
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
14/05/2026
First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized treatment planning MALVERN, Pa., May [...]
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
14/05/2026
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a best-in- [...]
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
14/05/2026
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention [...]
Biogen Completes Acquisition of Apellis Pharmaceuticals
14/05/2026
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing [...]
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
14/05/2026
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and [...]
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
14/05/2026
Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across [...]
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
14/05/2026
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid [...]
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
14/05/2026
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in [...]

Pages